ITSN1
Basic information
Region (hg38): 21:33642400-33899861
Previous symbols: [ "SH3D1A", "ITSN" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- Inborn genetic diseases (2 variants)
- Autistic behavior (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ITSN1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 24 | 30 | ||||
missense | 107 | 118 | ||||
nonsense | 12 | |||||
start loss | 0 | |||||
frameshift | 4 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 3 | 6 | 4 | 13 | ||
non coding | 41 | 43 | ||||
Total | 3 | 6 | 120 | 33 | 50 |
Variants in ITSN1
This is a list of pathogenic ClinVar variants found in the ITSN1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
21-33718560-G-C | Benign (May 21, 2021) | |||
21-33718838-T-C | Uncertain significance (Sep 12, 2022) | |||
21-33718853-G-A | Uncertain significance (Mar 18, 2022) | |||
21-33721218-G-A | ITSN1-related disorder | Likely benign (Sep 01, 2024) | ||
21-33721267-A-G | Inborn genetic diseases | Uncertain significance (Sep 09, 2024) | ||
21-33722544-GT-G | Benign (May 12, 2021) | |||
21-33722544-G-GT | Benign (May 21, 2021) | |||
21-33722593-C-G | Uncertain significance (Apr 30, 2024) | |||
21-33722604-C-CT | Uncertain significance (Apr 22, 2022) | |||
21-33722650-T-C | Neurodevelopmental disorder | Uncertain significance (Jul 16, 2023) | ||
21-33735047-A-G | ITSN1-related disorder | Likely benign (Aug 06, 2019) | ||
21-33735057-A-G | Inborn genetic diseases | Uncertain significance (Jul 09, 2021) | ||
21-33735096-A-G | Inborn genetic diseases | Uncertain significance (Aug 12, 2024) | ||
21-33735102-A-G | Inborn genetic diseases | Uncertain significance (Oct 14, 2023) | ||
21-33735130-G-T | Uncertain significance (Dec 20, 2023) | |||
21-33735155-C-G | ITSN1-related disorder | Likely benign (Dec 05, 2023) | ||
21-33735156-C-T | Inborn genetic diseases | Uncertain significance (Apr 18, 2023) | ||
21-33750152-G-A | Nephrotic syndrome | Uncertain significance (-) | ||
21-33750178-G-T | Inborn genetic diseases | Uncertain significance (Mar 20, 2023) | ||
21-33750194-C-A | Uncertain significance (Jun 01, 2022) | |||
21-33750235-G-T | Inborn genetic diseases | Uncertain significance (Apr 18, 2023) | ||
21-33750246-T-C | ITSN1-related disorder | Benign (Feb 26, 2018) | ||
21-33750259-G-T | Neurodevelopmental disorder | Uncertain significance (Sep 02, 2022) | ||
21-33750262-C-T | Inborn genetic diseases | Uncertain significance (Feb 27, 2023) | ||
21-33750265-C-G | Inborn genetic diseases | Uncertain significance (Oct 20, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ITSN1 | protein_coding | protein_coding | ENST00000381318 | 39 | 257460 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 7.25e-7 | 125722 | 0 | 26 | 125748 | 0.000103 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.61 | 644 | 959 | 0.672 | 0.0000542 | 11253 |
Missense in Polyphen | 136 | 276.57 | 0.49173 | 3302 | ||
Synonymous | 0.341 | 356 | 364 | 0.977 | 0.0000218 | 3263 |
Loss of Function | 8.30 | 16 | 110 | 0.146 | 0.00000600 | 1195 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000314 | 0.000304 |
Ashkenazi Jewish | 0.0000994 | 0.0000992 |
East Asian | 0.000164 | 0.000163 |
Finnish | 0.0000464 | 0.0000462 |
European (Non-Finnish) | 0.000116 | 0.000114 |
Middle Eastern | 0.000164 | 0.000163 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Acts as guanine nucleotide exchange factor (GEF) specific for the CDC42 GTPase (By similarity). Adapter protein that may provide indirect link between the endocytic membrane traffic and the actin assembly machinery. May regulate the formation of clathrin-coated vesicles. Involved in endocytosis of integrin beta-1 (ITGB1) and transferrin receptor (TFR); internalization of ITGB1 as DAB2-dependent cargo but not TFR may involve association with DAB2. Isoform 1 could be involved in brain-specific synaptic vesicle recycling. Inhibits ARHGAP31 activity toward RAC1. {ECO:0000250, ECO:0000269|PubMed:11744688, ECO:0000269|PubMed:22648170}.;
- Pathway
- Developmental Biology;Signaling by GPCR;Signal Transduction;Vesicle-mediated transport;Membrane Trafficking;EPH-Ephrin signaling;EPHB-mediated forward signaling;Rho GTPase cycle;Signaling by Rho GTPases;Clathrin-mediated endocytosis;NRAGE signals death through JNK;Death Receptor Signalling;p75 NTR receptor-mediated signalling;Cargo recognition for clathrin-mediated endocytosis;Axon guidance;G alpha (12/13) signalling events;GPCR downstream signalling;Regulation of CDC42 activity;Internalization of ErbB1;EPHB forward signaling;Cell death signalling via NRAGE, NRIF and NADE
(Consensus)
Recessive Scores
- pRec
- 0.202
Intolerance Scores
- loftool
- 0.512
- rvis_EVS
- -2.01
- rvis_percentile_EVS
- 1.72
Haploinsufficiency Scores
- pHI
- 0.718
- hipred
- Y
- hipred_score
- 0.756
- ghis
- 0.570
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.871
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Itsn1
- Phenotype
- growth/size/body region phenotype; endocrine/exocrine gland phenotype; cellular phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- G protein-coupled receptor signaling pathway;small GTPase mediated signal transduction;viral process;positive regulation of kinase activity;regulation of Rho protein signal transduction;positive regulation of apoptotic process;negative regulation of neuron apoptotic process;ephrin receptor signaling pathway;synaptic vesicle endocytosis;regulation of small GTPase mediated signal transduction;positive regulation of protein kinase B signaling;membrane organization
- Cellular component
- cytosol;plasma membrane;clathrin-coated pit;lamellipodium;cell junction;endocytic vesicle;calyx of Held;presynaptic endocytic zone
- Molecular function
- guanyl-nucleotide exchange factor activity;Rho guanyl-nucleotide exchange factor activity;calcium ion binding;protein binding;kinase activator activity;protein-containing complex scaffold activity;proline-rich region binding